JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

AZN

73.59

-1.31%↓

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

AZN

73.59

-1.31%↓

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

AZN

73.59

-1.31%↓

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

AZN

73.59

-1.31%↓

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

JNJ

173.56

+1.32%↑

ABBV

198.07

-0.35%↓

AZN

73.59

-1.31%↓

ABT

134.42

+1.78%↑

UNH

250.68

+2.57%↑

Search

Novartis AG

Uždarymo kaina

116.79 0.8

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

116.52

Max

116.9

Pagrindiniai rodikliai

By Trading Economics

Pajamos

418M

4B

Pardavimai

660M

14B

P/E

Sektoriaus vid.

16.809

34.393

Pelnas, tenkantis vienai akcijai

2.42

Dividendų pajamingumas

3.46

Pelno marža

28.18

Darbuotojai

75,883

EBITDA

-5.8B

4.9M

Rekomendacijos

By TipRanks

Rekomendacijos

Neutralu

12 mėnesių prognozė

+5.92% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

3.46%

2.54%

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-11B

228B

Ankstesnė atidarymo kaina

115.99

Ankstesnė uždarymo kaina

116.79

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bearish Evidence

Novartis AG Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-08-07 05:47; UTC

Įsigijimai, susijungimai, perėmimai

Novartis Makes Takeover Approach for Avidity Biosciences, FT Says, Citing Sources

2025-07-17 14:26; UTC

Uždarbis

Novartis Launches Buyback of Up to $10 Billion, Lifts Profit Outlook -- 2nd Update

2025-07-17 06:49; UTC

Uždarbis

Novartis Launches Buyback of Up to $10 Billion, Lifts Profit Outlook -- Update

2025-07-17 05:41; UTC

Uždarbis

Novartis Lifts Profit Outlook After Growth in Sales, Earnings

2025-08-08 11:26; UTC

Rinkos pokalbiai

Novartis Is Getting Closer to Midterm Targets -- Market Talk

2025-08-08 11:07; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Novartis Has Room to Accelerate Dealmaking -- Market Talk

2025-08-08 10:51; UTC

Rinkos pokalbiai
Įsigijimai, susijungimai, perėmimai

Novartis's Midterm Prospects Look Better Than Roche's -- Market Talk

2025-08-05 10:40; UTC

Rinkos pokalbiai

Roche, Novartis Face Limited Tariff Headwinds for Now -- Market Talk

2025-07-17 11:36; UTC

Rinkos pokalbiai

Novartis CEO Urges Europe to Reform Drug-Pricing System -- Market Talk

2025-07-17 11:26; UTC

Rinkos pokalbiai

Novartis CEO Confident on Midterm Plan to Mitigate U.S. Tariff Hit -- Market Talk

2025-07-17 07:14; UTC

Rinkos pokalbiai

Retirement of Well-Regarded Executive a Loss for Novartis -- Market Talk

2025-07-17 07:02; UTC

Rinkos pokalbiai
Uždarbis

Novartis's Results Look Impressive -- Market Talk

2025-07-17 05:09; UTC

Uždarbis

Novartis 2Q Sales Grew 11% at Constant Currency

2025-07-17 05:08; UTC

Uždarbis

Novartis: Kirsch Will Continue as CFO, Member of Executive Committee Until March 2026

2025-07-17 05:06; UTC

Uždarbis

Novartis: Mehta's Appointment Is Effective March 2026

2025-07-17 05:05; UTC

Uždarbis

Novartis: Harry Kirsch Retires After 22 Years With Company

2025-07-17 05:05; UTC

Uždarbis

Novartis Names Mukul Mehta as CFO

2025-07-17 05:04; UTC

Uždarbis

Analysts Saw Novartis 2Q Net Profit at $3.815B

2025-07-17 05:04; UTC

Uždarbis

Analysts Saw Novartis 2Q Core Operating Profit at $5.75B

2025-07-17 05:04; UTC

Uždarbis

Analysts Saw Novartis 2Q Sales at $14.17B

2025-07-17 05:04; UTC

Uždarbis

Novartis 2Q Core Operating Profit $5.925B

2025-07-17 05:04; UTC

Uždarbis

Novartis 2Q Oper Pft $4.86B

2025-07-17 05:03; UTC

Uždarbis

Novartis 2Q Sales $14.05B

2025-07-17 05:01; UTC

Uždarbis

Novartis: Buyback to Be Completed by End of 2027

2025-07-17 05:01; UTC

Uždarbis

Novartis Starting Buyback of Up to $10B

2025-07-17 05:01; UTC

Uždarbis

Novartis Backs 2025 Sales View

2025-07-17 05:01; UTC

Uždarbis

Novartis Had Guided for Low Double-Digit Growth in Core Operating Profit at Constant Currency

2025-07-17 05:01; UTC

Uždarbis

Novartis Expects 2025 Core Operating Profit to Grow by Low Teens at Constant Currency

2025-07-17 05:00; UTC

Uždarbis

Novartis Raises 2025 Earnings View

2025-07-17 05:00; UTC

Uždarbis

Novartis AG 2Q Adj EPS $2.42

Akcijų palyginimas

Kainos pokytis

Novartis AG Prognozė

Kainos tikslas

By TipRanks

5.92% į viršų

12 mėnesių prognozė

Vidutinis 122.78 USD  5.92%

Aukščiausias 137.561 USD

Žemiausias 108 USD

Remiantis 3 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Novartis AG kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Neutralu

3 ratings

0

Pirkti

3

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

N/A / 112.63Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Bearish Evidence

Vidutinės trukmės periodas

Weak Bullish Evidence

Ilgalaikis periodas

Strong Bullish Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Novartis AG

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. The company also provides Pluvicto, lutetium Lu 177 vipivotide tetraxetan, indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer; and Lutathera, lutetium Lu 177 dotatate, a prescription medicine used to treat adults and children aged 12 years and older with gastroenteropancreatic neuroendocrine tumors. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. The company has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. It also has a research collaboration and license agreement with Schrödinger, Inc. to identify and develop various therapeutic candidates; and a strategic collaboration with Vyriad, Inc. for the discovery and development for vivo chimeric antigen receptor T-cell therapies. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.